(MM) (FURX) News

back in the day (2020) it was a promising company. no wonder it has been purchased by AbbVie. despite the allergy related name, they invented Botox!

193.00 Game-Changer: The FDA Approved Eye Drops That Replace Reading Glasses

The drops, known as pilocarpine, and sold by pharma outlet Allergan under the name “Vuity,” might help the 128 million people in the United States who are nearsighted.

One drop in each eye, according to the business, may enhance closeup eyesight for six to ten hours, according to CBS News.

https://www.zerohedge.com/medical/game-changer-fda-approved-eye-drops-replace-reading-glasses

Please don’t invest your grandkids money here.

It doesn't look to be trading?

Did you do any DD you can pass along?

anyone looking to buy today?

What happened here rcookr1?

That's a wrap!

ABBV completes $65B AGN acquisition:

https://www.allergan.com/News/Details/2020/05/AbbVie%20Inc%20Completes%20Acquisition%20of%20Allergan%20plc

The deal, announced in Jun 2019 (#msg-149577810), entitles each AGN share to receive 0.886 shares of ABBV plus $120.30 in cash, a nominal value of $194.69/sh (3% higher than the nominal value of $188.24/sh nominal value at the time of the deal announcement).

1Q20 worldwide Botox sales=$812.2M, -6% YoY, -20% QoQ*:

https://www.sec.gov/ix?doc=/Archives/edgar/data/1578845/000156459020022386/agn-10q_20200331.htm

• US therapeutic: $395.8M (-1% YoY, -15% QoQ*)
• US cosmetic: $212.7M (-7% YoY, -22% QoQ*)
--
US total: $608.5M (65% therapeutic; 35% cosmetic) was 75% of worldwide total


• Ex-US therapeutic: $89.3M (-1% YoY, -13% QoQ*)
• Ex-US cosmetic: $114.4M (-21% YoY, -37% QoQ*)
--
Ex-US total: $203.7M (44% therapeutic; 56% cosmetic) was 25% of worldwide total


*Apart from the COVID-19 pandemic, Botox sales are seasonally stronger in the second and fourth calendar quarters than in the first and third quarters.

ABBV-AGN merger expected to close 5/8/20:

https://finance.yahoo.com/news/announcement-relating-outcome-court-sanction-105500126.html

Following FTC agreement, ABBV-AGN plan May 2020 merger closing:

https://www.prnewswire.com/news-releases/abbvie-and-allergan-sign-consent-decree-agreement-with-federal-trade-commission-staff-on-pending-transaction-301025767.html

ABBV-AGN receive EU approval for merger—US FTC approval still pending:

https://finance.yahoo.com/news/abbvie-allergan-receive-final-european-130000384.html

4Q19 worldwide Botox sales=$1.020B, +8% YoY, +10% QoQ*:

https://allergan.gcs-web.com/node/22536/pdf

• US therapeutic: $463.0M (+7% YoY, +7% QoQ*)
• US cosmetic: $271.8M (+6% YoY, +14% QoQ*)
--
US total: $734.8M (63% therapeutic; 37% cosmetic) was 72% of worldwide total


• Ex-US therapeutic: $102.5M (+9% YoY, +9% QoQ*)
• Ex-US cosmetic: $182.9M (+20% YoY, +10% QoQ*)
--
Ex-US total: $285.4M (36% therapeutic; 64% cosmetic) was 28% of worldwide total


*Botox sales are seasonally stronger in the second and fourth calendar quarters than in the first and third quarters.

FDA approves AGN’s Ubrelvy (ubrogepant) for acute migraine treatment:

https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-migraine

Ubrelvy may do well in the crowded CGRP arena because it’s oral.

AGN has a second oral CGRP candidate, Atogepant, in development for migraine prevention.

AGN acquired both drugs from MRK in 2015 for what now appears to be a very reasonable price (#msg-115206907).

3Q19 worldwide Botox sales=$928.7M, +6% YoY, -5% QoQ*:

https://www.allergan.com/News/Details/2019/11/Allergan%20Reports%20Third%20Quarter%202019%20Financial%20Results

• US therapeutic: $431.6M (+6% YoY, -3% QoQ*)
• US cosmetic: $237.6M (+10% YoY, -6% QoQ*)
--
US total: $669.2M (64% therapeutic; 36% cosmetic) was 72% of worldwide total


• Ex-US therapeutic: $93.9M (+5% YoY [constant currency], -5% QoQ*)
• Ex-US cosmetic: $165.6M (+6% YoY [constant currency], -6% QoQ*)
--
Ex-US total: $259.5M (36% therapeutic; 64% cosmetic) was 28% of worldwide total


*Botox sales are seasonally stronger in the second and fourth calendar quarters than in the first and third quarters.

2Q19 worldwide Botox sales=$974.0M, +4% YoY, +12% QoQ*:

https://www.allergan.com/News/News/Thomson-Reuters/Allergan-Reports-Second-Quarter-2019-Financial-Res

• US therapeutic: $447.0M (+6% YoY, +12% QoQ)
• US cosmetic: $252.4M (+7% YoY, +10% QoQ)
--
US total: $699.4M (64% therapeutic; 36% cosmetic)


• Ex-US therapeutic: $98.8M (+1% YoY [constant currency], +5% QoQ)
• Ex-US cosmetic: $175.8M (+11% YoY [constant currency], +19% QoQ)
--
Ex-US total: $274.6M (36% therapeutic; 64% cosmetic)


*Botox sales are seasonally stronger in the second and fourth calendar quarters than in the first and third quarters.

agn looking to buy EYEN. still a no brainer

LOL. These lawsuit PRs are pre-written fill-in-the-blanks forms ready to go at any moment.

News: $AGN Allergan Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Allergan plc is Fair to Shareholders - AGN

NEW YORK, June 25, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Allergan plc (NYSE: AGN) to AbbVie Inc. (“AbbVie”) is fair to Allergan shareholders. On behalf of Allergan shareholders, Halper Sadeh LLP may s...

Find out more https://marketwirenews.com/news-releases/allergan-merger-investigation-halper-sadeh-llp-announces-investigation-into-whether-the-sale-of-allergan-plc-is-fair-to-shareholders-agn-8411800.html

ABBV-AGN CC slides:

https://investors.abbvie.com/static-files/7b4c052f-bf32-4917-a239-0c1c9416550a

News: $AGN AbbVie to Acquire Allergan in Transformative Move for Both Companies

NORTH CHICAGO , Ill. and DUBLIN , June 25, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and Allergan plc (NYSE: AGN)  announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction...

In case you are interested https://marketwirenews.com/news-releases/abbvie-to-acquire-allergan-in-transformative-move-for-both-companies-8409708.html

RF-frequency devices for aesthetic applications go back at least 15 years to a company called Thermage (#msg-3876193). The THRM device never sold well and ended up being a swanky coat hanger at many doctor’s offices (#msg-11593419, #msg-29182011). THRM, which became SLTM, was eventually bought by Valeant Pharmaceuticals (the ultimate roll-up company) in 2013.

THRM’s device used RF-frequency waves to heat cells. I’m unclear how RF can used to cool cells, as AGN’s CoolTone supposedly does.

The Zeltiq device is cryogenic and seems to work according to a couple of relatives that have tried it. The cool tone device is magnetic and not as proprietary. There are already devices on the market such as the one below. I would like to see the data supporting the claim that 1.35T gives better results than 0.9T.

https://www.venusconcept.com/en-us/venus-freeze-plus.htm

https://www.venusconcept.com/en-us/venus-legacy.htm

~ 60% more effective then laser removal. Shorter treatments (2 months average vs ~ 1 year avg removal) without inflicting pain on clients.

Do some more Dewdiligence on it.

[OT]—I would question the business plan of any company that’s working on cellulite.

What’s differentiating about SOLY as compared to tattoo removal by laser?

In regards to AGN.. Has anyone heard of SOLY yet? The board of the company was recently involved with a similar company that developed a breakthrough fat reduction therapy that was purchased by AGN for 56$ ps or 2.4B.

$SOLY has patented technology on industry leading tattoo removal (RAP) & they announce their trial results for cellulite removal today.

AGN 1Q19 CC transcript:

https://finance.yahoo.com/news/edited-transcript-agn-earnings-conference-123003495.html

AGN 1Q19 CC slides:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzg1NzN8Q2hpbGRJRD03MDY1MjY=

(From AGN’s PR)—1Q19 worldwide Botox sales=$868.4M, +6% YoY (-8% QoQ*):

• US therapeutic: $397.6M (+6 YoY, -8% QoQ*)
• US cosmetic: $229.5M (+17% YoY, -11% QoQ*)
--
Total US sales: $627.1M (63% therapeutic, 37% cosmetic)


• Ex-US therapeutic: $93.9 (+7% YoY, -3% QoQ*)
• Ex-US cosmetic: $147.4M (+9% YoY, -7% QoQ*)
--
Total ex-US sales = $241.3M (39% therapeutic, 61% cosmetic)


*The 1Q19 QoQ decline relative to 4Q18 was expected; Botox is seasonally stronger in the second and fourth quarters of the calendar year.

AGN 1Q19 results:

https://www.allergan.com/News/News/Thomson-Reuters/Allergan-Reports-First-Quarter-2019-Financial-Resu

Abicipar pegol (a/k/a DARPin) shows 8.9% ocular inflammation in open-label study with new manufacturing process—lower than the 15% rate in prior phase-3 trials, but still too high to be competitive (IMO):

https://finance.yahoo.com/news/allergan-molecular-partners-announce-topline-110000485.html

AGN, by its own admission, was aiming for an inflammation rate in the low-to-mid single digits.

Three phase-3 Rapastinel trials stopped for futility:

https://www.prnewswire.com/news-releases/allergan-announces-phase-3-results-for-rapastinel-as-an-adjunctive-treatment-of-major-depressive-disorder-mdd-300808044.html

AGN 4Q18 CC transcript:

https://finance.yahoo.com/news/edited-transcript-agn-earnings-conference-213849663.html

AGN 4Q18 CC slides:

https://www.allergan.com/news/assets/q4-2018-earnings-deck_final

AGN 4Q18 results:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzcwMDh8Q2hpbGRJRD03MDM1MTE=

News: $AGN CoolSculpting® and Sonja Morgan Partner To Get Real About Self-Care

DUBLIN , Jan. 15, 2019 /PRNewswire/ -- Television personality on Bravo's "The Real Housewives of New York City ", philanthropist, fashion lifestyle entrepreneur and mom, Sonja Morgan , is partnering with CoolSculpting, owned by Allergan plc (NYSE: AGN), as the face of the brand's l...

Read the whole news https://marketwirenews.com/news-releases/coolsculpting-xae-and-sonja-morgan-partner-to-get-real-about-self-care-6831048.html

AGN -7% on permanent recall of “textured” breast implants in Europe:

https://finance.yahoo.com/news/allergan-suspends-sales-withdraws-supply-133000863.html

AGN 3Q18 CC transcript:

https://finance.yahoo.com/news/allergan-plc-agn-q3-2018-164449472.html

Reason for today’s selloff: #msg-144555471.

AGN 3Q18 results items…

PR:
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzU1Mjd8Q2hpbGRJRD03MDEwNzI=

CC slides:
https://www.allergan.com/news/assets/final-deck-q3-2018-10-30-2018.aspx

AGN slides from AAO webcast:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzU4MTF8Q2hpbGRJRD03MDA5ODI=

AGN slides from Medical Aesthetics Day:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzQ0Nzh8Q2hpbGRJRD02OTk5MDQ=

Re: AGN's internal long-acting toxin

#msg-143560931
#msg-143560695

AGN acquires (private) Bonti for $195M plus contingencies:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143556549

Bonti’s product candidate is a type-E botulinum toxin, which is an altogether different animal from type-A botulinum toxins such as Botox and RVNC’s RT002.

I previously commented on Bonti in #msg-137948777 and #msg-137955390.

AGN receives CRL for Ulipristal treatment for uterine fibroids:

https://www.prnewswire.com/news-releases/allergan-receives-complete-response-letter-from-the-us-food-and-drug-administration-for-ulipristal-acetate-new-drug-application-300700400.html

AGN, EDIT announce mutual opt-ins on EDIT-101: #msg-142720697.

More granularity of 2Q18 Botox sales: #msg-142479825.

Transcript of AGN 2Q18 CC:

https://finance.yahoo.com/news/edited-transcript-agn-earnings-conference-213321827.html

AGN 2Q18 items…

PR:
https://finance.yahoo.com/news/allergan-reports-strong-second-quarter-103000561.html

CC slides:
http://www.allergan.com/news/assets/q2-2018-earnings-presentation.pdf

AGN/MOLN.SW report phase-3 AMD data for Abicipar (a/k/a DARPin):

#msg-142311304

AGN 1Q18 CC transcript:

https://finance.yahoo.com/news/edited-transcript-agn-earnings-conference-224140279.html